Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prediction of the Response to Anti-TNFs DMARDs Based on the RheumaKit ® Platform (RK-Tx-01)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by DNAlytics
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Information provided by (Responsible Party):
DNAlytics Identifier:
First received: September 6, 2016
Last updated: January 27, 2017
Last verified: January 2017
RA is the most common inflammatory, persistent and progressive disease of the joints with serious co-morbidities and huge health and socio-economic impact worldwide.

Condition Intervention
Rheumatoid Arthritis
Other: RheumaKit: Prediction of the response to anti-TNFs DMARDs

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Diagnostic
Official Title: Prediction of the Response to Anti-TNFs DMARDs Based on the RheumaKit ® Platform (RK-Tx-01)

Resource links provided by NLM:

Further study details as provided by DNAlytics:

Primary Outcome Measures:
  • Ability of a score [ Time Frame: Up to 12 months ]
    To show the ability of a score, computed prior to treatment initiation, to be predictive of the individual anti-TNF response. The score is based on the RheumaKit transcriptomic profiles from a set of small synovial biopsies from a given joint also harvested before anti-TNF treatment initiation.

Secondary Outcome Measures:
  • Identify additional/alternative mappings [ Time Frame: Up to 12 months ]
    To identify additional/alternative mappings between components of gene expression profiles obtained via the RheumaKit assay (extended, and possibly combined to clinical and biological information) and efficacy of anti-TNFs biological DMARDs.

  • Validate the sample logistics at an international scale. [ Time Frame: Up to 12 months ]
    To validate the feasibility of the implementation of a molecular biology test in rheumatology based on synovial tissue at an international scale. This covers both logistics and patient agreeableness aspects.

Estimated Enrollment: 110
Study Start Date: November 2016
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: All patients
All eligible patients
Other: RheumaKit: Prediction of the response to anti-TNFs DMARDs

Detailed Description:
The current standard therapeutic strategy for RA patients is to initiate a DMARDs therapy, (e.g. MTX) with serious side effects. This also applies to some PSO or SNSA patients. MTX is however inefficient in about 40% of the cases. Other treatments (biological DMARDs) must thus be initiated, which have an overall similar effectiveness and side effects and an higher cost (around 13kEUR/year/patient). Therapeutic choices are based on symptoms and blood tests including markers of inflammation which are inadequate to predict disease evolution and response to treatments. Improving RA management requires to improve the adequacy of the therapeutic strategies. The earlier the disease is correctly addressed, the more likely its progression and irreversible damages to the joints will be limited. DNAlytics recently developed RheumaKit a differential diagnostic solution for UA patients. UA is a condition in which joint inflammation is present, but a precise diagnosis cannot be made, due to the lack of sensitivity of presently available diagnostic techniques. RheumaKit is a multi-gene expression solution that discriminates RA from other joint conditions. A diagnostic model train to identify patients suffering from RA, SNSA or OA. RheumaKit diagnostic accuracy is higher than 90%, a performance that is better than any other diagnostic solution designed until now, including the ACR/EULAR 2010 criteria for the diagnosis of RA. See working principle below. Beyond diagnosis, DNAlytics wants to make RheumaKit evolve towards treatment recommendation applications (theranostic applications) for patients eligible for biological DMARDs. On one hand, the diseases of these patients have been more and more described in terms of the activity of several metabolic pathways (T & B cells activation, Extra cellular matrix, Inteferon, TNF). On the other hand, the existing treatments also have been more and more described in terms of the pathways they target. The RheumaKit signature contains many markers that are representative of these pathways of interest. RheumaKit thus now provides a snapshot of the activity of seven metabolic pathways known from literature to be related to diseases mechanisms, or to be target of existing treatments. In this study, DNAlytics wants to show that based on a score defined on the RheumaKit platform, the response or non- response to anti-TNFs, representing the largest category of biological DMARDs, can be predicted before treatment initiation.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients must satisfy all of the following criteria:

  • Signed the ICF and covered by health insurance.
  • At least 18 years old.
  • For women, use of a reliable method of birth control or remain abstinent during the study, or have had surgical sterilization or women above 60 years of age.
  • Having undergone at least 3 months of synthetic DMARD treatment while being strictly eligible for it (diagnosed with RA) and being at a stable dose at least for the last month, and showing no satisfactory response to this therapy.
  • Be eligible for biological DMARD treatment according to local regulation and practice.
  • Willing and able to comply with scheduled visits, treatment plan, tests and other protocol procedures.

Exclusion Criteria:

Patients must satisfy none of the following criteria:

  • Arthritis history longer than 5 years.
  • Biological DMARD therapy already initiated.
  • Be diagnosed with septic arthritis.
  • Be pregnant or breastfeeding/lactating women.
  • Diagnosed with HIV, hepatitis B, hepatitis C, Crohn's disease, fibromyalgia.
  • Diagnosed with other inflammatory arthritic syndrome than RA.
  • have a chronic pain condition that would confound evaluation of the patient.
  • Be identified as at too high risk for biopsy or for biologic therapy.
  • Be identified as having psychological, familial, social or geographical conditions which could potentially hamper compliance with the study protocol and follow-up schedule.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02928276

Contact: Helleputte Thibault, PhD +32 10 39 00 96

Clinique Universitaires Saint-Luc Recruiting
Brussels, Bruxelles-capital, Belgium, 1200
Contact: Aurore Maboge, MSc    +32 2 764 79 80   
Principal Investigator: Patrick Durez, MD         
Sub-Investigator: Bernard Lauwerys, PhD         
CHU Liège Recruiting
Liège, Belgium
Contact: Anja Volders   
Principal Investigator: Michel Malaise         
Sponsors and Collaborators
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Principal Investigator: Patrick Durez, MD Clinique Universitaire Saint-Luc
  More Information

Responsible Party: DNAlytics Identifier: NCT02928276     History of Changes
Other Study ID Numbers: RK-Tx-01
Study First Received: September 6, 2016
Last Updated: January 27, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by DNAlytics:
Rheumatoid Arthritis

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Antirheumatic Agents processed this record on April 27, 2017